CIDRAP News: TB vaccine candidate shows sustained protection
“In a promising development that seems to put the world a step closer to a better vaccine against tuberculosis (TB), researchers [Tuesday] published final results from a phase 2b trial, which showed nearly 50% protection against progression to active TB. The findings confirm earlier results first reported in 2018 for the adjuvanted subunit vaccine (M72/AS01E) developed by GlaxoSmithKline (GSK) and the International AIDS Vaccine Initiative (IAVI). Researchers published their findings [Tuesday] in the New England Journal of Medicine and presented them at the 50th Union World Congress on Lung Health in Hyderabad, India…” (Schnirring, 10/29).

Additional coverage of the trial results is available from The BMJ, MedPage Today, and Science Speaks.